Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01153282 · ClinicalTrials.gov registry record

Physical Functional Side Effects of Taxane Chemotherapy for Breast Cancer

A clinical trial, sponsored by Abramson Cancer Center at Penn Medicine.

Completed
Registry status
25
Enrollment target

NCT01153282: Completed study, sponsored by Abramson Cancer Center at Penn Medicine.

NCT01153282 is a clinical trial that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01153282 has completed, sponsored by Abramson Cancer Center at Penn Medicine.

COMPLETED
Registry status
25 participants
Enrollment target

Study Summary

Determine the characteristics of symptoms and functional impairment associated with chemotherapy induced peripheral neuropathy.

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2010-06
Est. Completion 2012-05

What the finished NCT01153282 record still lists

NCT01153282 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 25 participants, a relatively small participant target.

The record links to 0 conditions, and to 0 interventions.

NCT01153282 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01153282 about?

NCT01153282 is a clinical study titled "Physical Functional Side Effects of Taxane Chemotherapy for Breast Cancer". Determine the characteristics of symptoms and functional impairment associated with chemotherapy induced peripheral neuropathy.

What is the current status of trial NCT01153282?

This trial is currently completed. The enrollment target is 25 participants. The study started on 2010-06. Estimated completion is 2012-05.

Who is sponsoring clinical trial NCT01153282?

This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01166854 · 25 participants

    Characterization of Familial Myopathy and Paget Disease of Bone

  • NCT01913106 · 25 participants · Phase 1

    HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer

  • NCT02138669 · 25 participants · NA

    Intacs Prescription Inserts for Keratoconus Patients

  • NCT02174549 · 25 participants · Phase 1

    Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01153282, the US trial registry maintained by the National Library of Medicine. NCT01153282 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.